Trial Profile
MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control after first line chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Anastrozole; Exemestane; Letrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms MAIN-A
- 02 Jul 2021 Primary endpoint (Progression free survival) has not been met, according to Results published in the European Journal of Cancer.
- 02 Jul 2021 Results published in the European Journal of Cancer.
- 02 Dec 2020 Status changed from active, no longer recruiting to completed.